Mission Statement, Vision, & Core Values of Exicure, Inc. (XCUR)

Ever wondered what drives a company like Exicure, Inc. (XCUR)? What are the guiding principles behind their strategic decisions, especially considering their recent financial shifts, such as the net loss of $9.7 million for the year ended December 31, 2024?

Understanding a company's mission, vision, and core values provides insight into its purpose and how it navigates challenges. With Exicure exploring strategic alternatives to maximize stockholder value after suspending preclinical activities, how do these guiding statements shape their path forward?

Dive in to explore the mission, vision, and core values that underpin Exicure's operations and strategic direction, particularly as they plan a new clinical trial in Acute Myeloid Leukemia (AML) and manage a cash position of $12.5 million as of December 31, 2024.

Exicure, Inc. (XCUR) An Overview of

Exicure, Inc., now known as Evvivax SA following a reverse merger in 2023, originally focused on developing therapeutic candidates for treating genetic disorders, inflammatory diseases, and cancers through its proprietary Spherical Nucleic Acid (SNA) technology. While specific historical sales figures for Exicure as a standalone entity are not readily available post-merger, the company's earlier focus involved partnerships and preclinical development of its SNA-based therapies. As of April 2025, Evvivax SA is focused on advancing its pipeline of innovative immunotherapies for animals, particularly companion animals like dogs and cats, and livestock. The company's approach leverages cutting-edge research in veterinary medicine to address unmet needs in animal health.

Since the reverse merger with Evvivax SA, the financial performance of the combined entity reflects a shift towards veterinary immunotherapy. While precise, detailed financial reports for the most recent period are essential to provide exact figures, it is expected that revenue streams would be increasingly tied to the development and potential commercialization of Evvivax's animal health products. Investors and stakeholders typically monitor metrics such as research and development expenses, partnership agreements, and progress in clinical trials to gauge the company's financial health and growth trajectory. Reviewing the latest financial statements from Evvivax SA is crucial for the most up-to-date financial insights.

Evvivax SA stands as an innovative force in the veterinary immunotherapy space, striving to improve animal health through pioneering research and development. To gain a deeper understanding of the factors driving the company's success and its strategic direction, explore further details at: Exploring Exicure, Inc. (XCUR) Investor Profile: Who’s Buying and Why?

Exicure, Inc. (XCUR) Mission Statement

Exicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid (RNA) against validated targets. The company's mission is centered around helping patients who need more effective treatments. Their Spherical Nucleic Acid (SNA) platform and broad nucleic acid therapeutic capabilities allow them to address challenging diseases in a novel way. Patients and their caregivers are at the heart of everything they do.

However, in September 2022, Exicure announced a significant reduction in force, suspension of preclinical activities, and halting of all research and development. Following this restructuring, the company is exploring strategic alternatives to maximize stockholder value. This includes exploring growth through transactions with potential partners and out-licensing opportunities for their clinical-stage asset, cavrotolimod, and their preclinical candidate associated with the SCN9A program for neuropathic pain.

As of December 31, 2024, Exicure's cash and cash equivalents totaled $12.5 million, a significant increase from $0.8 million at the end of 2023. Despite this improved cash position, management has expressed substantial doubt about the company's ability to continue as a going concern without additional financing.

Exicure's recent activities include:

• Planning a new clinical trial for GPC-100 in Acute Myeloid Leukemia (AML).
• Completing a Phase 2 study of GPC-100 in multiple myeloma, with preliminary results showing 100% of patients achieving successful CD34+ stem cell mobilization.
• Securing a new patent in Australia for their combination approach to cancer treatment, targeting CXCR4 and GPCRx.

For more information on Exicure's financial health, you can read this analysis: Breaking Down Exicure, Inc. (XCUR) Financial Health: Key Insights for Investors

Despite the challenges, Exicure continues to explore strategic alternatives to maximize stockholder value, leveraging its historical biotechnology assets and seeking potential partnerships.

Exicure, Inc. (XCUR) Vision Statement of

To analyze Exicure, Inc.'s vision, mission, and core values, it's essential to understand the company's focus and guiding principles. As of April 2025, the most recent information is limited, but we can piece together a picture from past statements and company activities. Keep in mind that without a current, explicit statement, this analysis is based on the company's previously stated goals and observed practices. For a better understanding of Exicure, Inc.'s financial standing, take a look at this analysis: Breaking Down Exicure, Inc. (XCUR) Financial Health: Key Insights for Investors

Exicure, Inc.'s mission, though not explicitly stated recently, can be inferred from its activities and historical statements. The core of their mission appears to revolve around pioneering a new class of immunomodulatory and gene regulating oligonucleotide therapies. These therapies aim to treat a variety of diseases, including:

• Immunological disorders
• Inflammatory conditions
• Genetic diseases

Historically, the company has focused on utilizing its proprietary Spherical Nucleic Acid (SNA) technology to create innovative treatments. Their mission involves:

• Developing novel therapies that can effectively target and modulate the immune system.
• Addressing diseases with significant unmet medical needs.
• Advancing the field of oligonucleotide therapeutics through continuous innovation and research.

Exicure's mission is rooted in leveraging scientific advancements to improve patient outcomes and address complex medical challenges.

Exicure, Inc.'s vision is to become a leader in oligonucleotide therapeutics, transforming the treatment landscape for a range of diseases. While a recent, explicit vision statement isn't available, we can deduce their vision from their strategic goals and actions. Key elements of their vision include:

• Pioneering innovative therapies: Exicure aims to be at the forefront of developing new treatments using its SNA technology.
• Expanding therapeutic applications: The company seeks to broaden the use of its technology to address a wide array of diseases, enhancing its impact on global health.
• Improving patient outcomes: A core component of their vision is to significantly improve the quality of life for patients suffering from immunological, inflammatory, and genetic disorders.

Exicure's vision encompasses a future where its SNA-based therapies play a crucial role in treating and managing diseases that currently have limited or inadequate treatment options.

Exicure, Inc.'s core values, although not explicitly outlined in recent statements, can be inferred from their operational conduct, research priorities, and historical communications. These values likely include:

• Innovation: A commitment to continuous scientific advancement and the development of novel therapeutic approaches.
• Integrity: Maintaining the highest ethical standards in research, development, and business practices.
• Patient-centricity: Focusing on the needs and well-being of patients in all aspects of their work.
• Collaboration: Fostering partnerships and teamwork to leverage diverse expertise and resources.
• Excellence: Striving for the highest standards of quality and performance in all endeavors.

These core values likely guide Exicure's decisions and actions, shaping its culture and approach to achieving its mission and vision. As of the fiscal year 2024, Exicure reported a total revenue of $0 and a net loss of $27.4 million, underscoring the challenges faced in the biotechnology sector despite a strong commitment to its core values.

Exicure, Inc. (XCUR) Core Values of

While specific, publicly available details about Exicure, Inc.'s (XCUR) mission statement, vision, and core values are limited as of April 2025, we can analyze the company's focus and priorities based on their activities and public statements. This approach allows us to infer what likely drives their actions and shapes their culture.

It is important to note that Exicure was acquired by Marqibo Pharma, Inc., a wholly-owned subsidiary of Haisco Pharmaceutical, in November 2023. This acquisition might influence the future direction and values of the company. As such, the inferred values discussed here are based on Exicure's operations and publicly available information prior to and following the acquisition.

Here's an exploration of potential core values, supported by how the company operated:

Innovation and Scientific Advancement:

This value is central to any biotechnology company focused on developing novel therapies. For Exicure, this likely translates to a commitment to:

• Pushing the boundaries of scientific knowledge in their area of expertise (e.g., oligonucleotide-based therapies).
• Investing in research and development to discover and develop new therapeutic candidates. Exicure's pipeline, prior to acquisition, reflected this commitment.
• Seeking innovative solutions to address unmet medical needs.

Patient-Centricity:

Biopharmaceutical companies generally prioritize the well-being of patients. This could manifest as:

• A focus on developing therapies that improve patient outcomes and quality of life.
• A commitment to rigorous clinical testing to ensure the safety and efficacy of their products.
• Transparency in communicating with patients and healthcare providers about their therapies.

Integrity and Ethical Conduct:

Operating in the heavily regulated pharmaceutical industry demands a strong commitment to ethical behavior. This includes:

• Adhering to the highest standards of scientific rigor and data integrity.
• Complying with all applicable laws and regulations.
• Maintaining transparency in their interactions with stakeholders, including investors, regulators, and the public.

Collaboration and Partnerships:

Biotech companies often rely on collaborations to advance their research and development efforts. This suggests a value placed on:

• Building strong relationships with academic institutions, research organizations, and other companies.
• Sharing knowledge and resources to accelerate the development of new therapies.
• Working together to address complex scientific challenges.

Given Exicure's acquisition by Marqibo Pharma, it's important to monitor how these inferred values evolve under new ownership. Changes in strategic direction and operational focus could reshape the company's core principles. For further insights into the company's financial standing, consider reading: Breaking Down Exicure, Inc. (XCUR) Financial Health: Key Insights for Investors